Clinical Trials
37 trialsPD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
M.D. Anderson Cancer Center
REACTION
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
University of Wisconsin, Madison
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
CONGRATS
Institut Bergonié
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NYU Langone Health
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
NICHE
The Netherlands Cancer Institute
Neo IRENIE
Melanoma Institute Australia
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Melanoma Institute Australia
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Neo ReNi II
Melanoma Institute Australia
NEON
University of California, San Diego
NOBLE
National Health Research Institutes, Taiwan
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TURANDORELA
The Netherlands Cancer Institute
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
M.D. Anderson Cancer Center
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
University of Pittsburgh
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Royal Marsden NHS Foundation Trust
NEOpredict
University Hospital, Essen
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
Jonsson Comprehensive Cancer Center
Neoadjuvant and Adjuvant Checkpoint Blockade
M.D. Anderson Cancer Center
IMAGINE
University Hospital, Essen
AARON
Ludwig-Maximilians - University of Munich
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Vanderbilt-Ingram Cancer Center